DK1542729T3 - Stabilt immunogent produkt omfattende antigene heterokomplekser - Google Patents

Stabilt immunogent produkt omfattende antigene heterokomplekser

Info

Publication number
DK1542729T3
DK1542729T3 DK03772373.1T DK03772373T DK1542729T3 DK 1542729 T3 DK1542729 T3 DK 1542729T3 DK 03772373 T DK03772373 T DK 03772373T DK 1542729 T3 DK1542729 T3 DK 1542729T3
Authority
DK
Denmark
Prior art keywords
immunogenic product
stable immunogenic
antigenic heterocomplexes
heterocomplexes
antigenic
Prior art date
Application number
DK03772373.1T
Other languages
English (en)
Inventor
Buanec Helene Le
Daniel Zagury
Original Assignee
Neovacs
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Neovacs filed Critical Neovacs
Application granted granted Critical
Publication of DK1542729T3 publication Critical patent/DK1542729T3/da

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/385—Haptens or antigens, bound to carriers
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A61P31/14—Antivirals for RNA viruses
    • A61P31/18—Antivirals for RNA viruses for HIV
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/04—Immunostimulants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/08—Antiallergic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6075—Viral proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/60—Medicinal preparations containing antigens or antibodies characteristics by the carrier linked to the antigen
    • A61K2039/6031—Proteins
    • A61K2039/6081—Albumin; Keyhole limpet haemocyanin [KLH]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/62—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier
    • A61K2039/622—Medicinal preparations containing antigens or antibodies characterised by the link between antigen and carrier non-covalent binding
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/0005—Vertebrate antigens
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/6415—Toxins or lectins, e.g. clostridial toxins or Pseudomonas exotoxins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/643—Albumins, e.g. HSA, BSA, ovalbumin or a Keyhole Limpet Hemocyanin [KHL]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • A61K47/646—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent the entire peptide or protein drug conjugate elicits an immune response, e.g. conjugate vaccines

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Epidemiology (AREA)
  • Molecular Biology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Microbiology (AREA)
  • Mycology (AREA)
  • Virology (AREA)
  • Toxicology (AREA)
  • Oncology (AREA)
  • Pulmonology (AREA)
  • AIDS & HIV (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Communicable Diseases (AREA)
  • Hematology (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Peptides Or Proteins (AREA)
  • Medicinal Preparation (AREA)
DK03772373.1T 2002-09-16 2003-09-16 Stabilt immunogent produkt omfattende antigene heterokomplekser DK1542729T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0211455A FR2844514B1 (fr) 2002-09-16 2002-09-16 Produit immunogene stable comprenant des heterocomplexes antigeniques, compositions les contenant et procede de preparation
PCT/FR2003/002733 WO2004024189A1 (fr) 2002-09-16 2003-09-16 Produit immunogene stable comprenant des heterocomplexes antigeniques

Publications (1)

Publication Number Publication Date
DK1542729T3 true DK1542729T3 (da) 2014-02-10

Family

ID=31897411

Family Applications (1)

Application Number Title Priority Date Filing Date
DK03772373.1T DK1542729T3 (da) 2002-09-16 2003-09-16 Stabilt immunogent produkt omfattende antigene heterokomplekser

Country Status (13)

Country Link
US (3) US7972603B2 (da)
EP (1) EP1542729B1 (da)
JP (2) JP4698223B2 (da)
CN (1) CN1723041B (da)
AU (1) AU2003279427B2 (da)
BR (1) BRPI0314373B8 (da)
CA (1) CA2499214C (da)
DK (1) DK1542729T3 (da)
ES (1) ES2445331T3 (da)
FR (1) FR2844514B1 (da)
NZ (1) NZ538835A (da)
WO (1) WO2004024189A1 (da)
ZA (1) ZA200502184B (da)

Families Citing this family (25)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN101512013A (zh) * 2005-03-23 2009-08-19 生物-拉德实验室公司 与具有顺磁性质的小颗粒相连接的各种化学库
EP1888122B1 (en) * 2005-05-24 2011-03-09 Neovacs A method for preparing a stable immunogenic product comprising antigenic heterocomplexes of tnf alpha and a carrier protein
BRPI0619436A2 (pt) * 2005-12-05 2011-10-04 Nitto Denko Corp métodos e conjugados de aminoácido-poliglutamato
JP2009536951A (ja) * 2006-05-12 2009-10-22 オクラホマ メディカル リサーチ ファウンデーション 炭疽菌組成物ならびに使用および生成方法
CN101553246B (zh) * 2006-08-07 2019-05-21 哈佛大学校长及研究员协会 蛋白质基质疫苗及这种疫苗的制备和给药方法
US20080181852A1 (en) * 2007-01-29 2008-07-31 Nitto Denko Corporation Multi-functional Drug Carriers
CN101674852A (zh) * 2007-04-10 2010-03-17 日东电工株式会社 多功能聚谷氨酸盐药物载体
US8197828B2 (en) * 2007-05-09 2012-06-12 Nitto Denko Corporation Compositions that include a hydrophobic compound and a polyamino acid conjugate
CU23652A1 (es) * 2007-06-29 2011-05-27 Centro Inmunologia Molecular Composición vacunal homogénea para el tratamiento del cáncer y su método de obtención
JP2011513412A (ja) * 2008-03-06 2011-04-28 日東電工株式会社 ポリマーパクリタキセル結合体を含む癌を治療するための薬学組成物
CN102008719A (zh) * 2010-12-02 2011-04-13 上海微球生物科技有限公司 克服b细胞免疫耐受的免疫微球及其应用
RU2013125147A (ru) 2010-12-08 2015-01-20 Неовакс Сильно инактивированная иммуногенная вакцина, сохраняющая высокую иммуногенность, и способ ее изготовления
EP2462950A1 (en) 2010-12-08 2012-06-13 Neovacs Strongly inactivated and still highly immunogenic vaccine, and process of manufacturing thereof
DK2694094T3 (da) 2011-04-07 2017-11-13 Neovacs FREMGANGSMÅDE TIL BEHANDLING AF IFN-alpha-RELATEREDE TILSTANDE
EP2861485A4 (en) 2012-06-13 2016-03-02 Auto Res Ct Llc POSITIVE CONVERGENCE DEVICE FOR A VEHICLE
US9199673B2 (en) 2012-10-30 2015-12-01 Wabash National, L.P. Aerodynamic rear drag reduction system for a trailer
US8973974B2 (en) * 2013-04-30 2015-03-10 Wabash National, L.P. Aerodynamic rear fairing system for a trailer
WO2015148459A1 (en) 2014-03-24 2015-10-01 Auto Research Center, Llc Wake convergence device for a pick-up truck
US9616944B2 (en) 2014-05-15 2017-04-11 Wabash National, L.P. Aerodynamic rear drag reduction system for a trailer
MX368079B (es) 2015-02-16 2019-09-18 Wabash National Lp Sistema de reduccion de resistencia aerodinamica posterior para un remolque.
MX2016005692A (es) 2015-04-29 2016-10-28 Wabash National Lp Sistema aerodinamico de reduccion de resistencia trasera para un remolque.
US9776674B2 (en) 2015-04-29 2017-10-03 Wabash National, L.P. Aerodynamic rear drag reduction system for a trailer
CN108289909A (zh) 2015-10-19 2018-07-17 巴尔的摩马里兰大学 用于产生工程改造的人原代血液树突细胞系的方法
CN108752480B (zh) * 2018-05-30 2022-03-29 中元汇吉生物技术股份有限公司 一种免疫原组合物、其制备方法及其用途
BR112021000965A2 (pt) * 2018-08-07 2021-04-27 Glaxosmithkline Biologicals S.A. processos e vacinas

Family Cites Families (20)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US98203A (en) * 1869-12-21 Improvement in elevators
FR2635532B1 (fr) 1988-07-29 1992-05-22 Pasteur Institut Particules hbsag recombinantes hybrides : caracteristiques morphologiques de l'antigene hbsag contenant 1 sequence immunogene induisant des anticorps neutralisants diriges contre hiv ou susceptible d'etre reconnue par de tels anticorps; sequences nucleotidiques codant pour de telles particules; vaccins les contenant
US5008116A (en) * 1988-11-14 1991-04-16 Frederick Cahn Immunostimulatory microsphere
SE467542B (sv) * 1989-06-13 1992-08-03 Syntello Ab Syntetiska peptidantigener, immuniserande komposition och immunanalys foer htlv-1 antikroppar
JPH04506662A (ja) * 1989-07-14 1992-11-19 アメリカン・サイアナミド・カンパニー 接合体ワクチンのためのサイトカイニンおよびホルモンのキヤリヤー
FR2677654B1 (fr) * 1991-06-17 1995-11-17 Pasteur Merieux Serums Vacc Composes a effet immunogene anti-cytokine, a effet immunogene anticytostatique ou a effet vaccinal anti-infection a hiv.
ATE196255T1 (de) 1995-03-08 2000-09-15 Neovacs Von einem retroviralen regulationsprotein abstammende, detoxifierte immunogene, dagegen gerichtete antikörper, verfahren zur deren herstellung und diese immunogene oder antikörper enthaltende, pharmazeutische zusammensetzungen.
FR2731355B1 (fr) * 1995-03-08 1997-05-30 Neovacs Nouveaux immunogenes, nouveaux anticorps, procede de preparation et compositions pharmaceutiques les renfermant
US6093045A (en) * 1996-03-13 2000-07-25 Osram Sylvania Inc. Electrical connector module and kit having tamper proof latch mechanism
US6340461B1 (en) * 1996-12-17 2002-01-22 David Stephen Terman Superantigen based methods and compositions for treatment of diseases
FR2759296B1 (fr) * 1997-02-07 1999-04-09 Commissariat Energie Atomique Complexe non-covalent comprenant au moins un anticorps et un element de liaison aux immunoglobulines associe a une substance active, son procede de preparation et ses applications
RU2241715C2 (ru) * 1997-04-15 2004-12-10 Фармекса А/С МОДИФИЦИРОВАННАЯ МОЛЕКУЛА ФНОα ЧЕЛОВЕКА, СПОСОБНАЯ ИНДУЦИРОВАТЬ ОБРАЗОВАНИЕ НЕЙТРАЛИЗУЮЩИХ АНТИТЕЛ К ЧЕЛОВЕЧЕСКОМУ ФНОα, ДНК, ЕЕ КОДИРУЮЩАЯ, ВЕКТОР (ВАРИАНТЫ), СПОСОБ ПОЛУЧЕНИЯ, ВАКЦИНА ПРОТИВ ФНОα (ВАРИАНТЫ), СПОСОБ ТЕСТИРОВАНИЯ НА ПРИСУТСТВИЕ ФНОα, СПОСОБ ТЕСТИРОВАНИЯ ЖИДКОСТЕЙ ТЕЛА ЧЕЛОВЕКА, СПОСОБ ДИАГНОСТИКИ, СПОСОБ ЛЕЧЕНИЯ И ПРОФИЛАКТИКИ, МЕДИКАМЕНТ ДЛЯ ЛЕЧЕНИЯ
JP3591264B2 (ja) * 1997-12-24 2004-11-17 富士レビオ株式会社 Ｖｅｇｆ１２１特異的モノクローナル抗体及び測定方法
EP1075184A4 (en) * 1998-05-08 2002-01-30 Sloan Kettering Inst Cancer ACTIVE VACCINATION COMPOSITIONS AND METHODS
FR2781158B1 (fr) * 1998-07-15 2002-12-13 Vacs Internat Nouvelles proteines modifiees immunogenes non immunosuppressives, leur procede de preparation et leurs applications
FR2792639B1 (fr) * 1999-04-26 2003-06-06 Neovacs Nouveaux immunogenes anti-vih (toxoides), nouveaux procedes de preparation et application a la prevention et au traitement du sida
MXPA01011570A (es) * 1999-05-13 2003-08-20 Australian Pork Ltd Gen derivado de lawsonia y polipeptidos, peptidos y proteinas relacionadas con peptido h de membrana externa.
FR2812813B1 (fr) * 2000-08-09 2004-11-26 Neovacs Utilisation d'immunogenes pour traiter ou prevenir au sein des tumeurs malignes les dereglements immunitaires induits par des facteurs extracellulaires
AUPR011700A0 (en) * 2000-09-14 2000-10-05 Austin Research Institute, The Composition comprising immunogenic virus sized particles (VSP)
EP1322290A1 (en) * 2000-10-06 2003-07-02 Jagotec Ag Vaccine composition comprising an immunologically active substance embedded in microparticles consisting of starch with reduced molecular weight

Also Published As

Publication number Publication date
AU2003279427B2 (en) 2008-12-18
BRPI0314373B8 (pt) 2021-05-25
JP2011012084A (ja) 2011-01-20
NZ538835A (en) 2006-07-28
US8372388B2 (en) 2013-02-12
US8697047B2 (en) 2014-04-15
CA2499214C (fr) 2014-02-11
ZA200502184B (en) 2005-12-28
CN1723041A (zh) 2006-01-18
FR2844514A1 (fr) 2004-03-19
WO2004024189A1 (fr) 2004-03-25
CN1723041B (zh) 2012-07-18
BR0314373A (pt) 2005-07-19
US7972603B2 (en) 2011-07-05
AU2003279427A1 (en) 2004-04-30
EP1542729A1 (fr) 2005-06-22
CA2499214A1 (fr) 2004-03-25
JP2006504689A (ja) 2006-02-09
US20060013800A1 (en) 2006-01-19
ES2445331T3 (es) 2014-03-03
BRPI0314373B1 (pt) 2019-11-05
US20060067944A1 (en) 2006-03-30
US20110250174A1 (en) 2011-10-13
JP4698223B2 (ja) 2011-06-08
FR2844514B1 (fr) 2007-10-19
EP1542729B1 (fr) 2013-11-06

Similar Documents

Publication Publication Date Title
DK1542729T3 (da) Stabilt immunogent produkt omfattende antigene heterokomplekser
IS7547A (is) Ónæmisvaldandi samsetningar
ATE388643T1 (de) Rauchloses tabakerzeugnis
PT1501534E (pt) Formulacoes farmaceuticas
CY2013036I1 (el) Συνθεσεις εμβολιου κατα της ναϊσσερια, που περιεχουν εναν συνδυασμο αντιγονων
IS7831A (is) Bóluefni
NO20035208D0 (no) Nytt vaksine preparat
ATE387214T1 (de) Impfstoff gegen bakterielle antigene
NO20050132D0 (no) Vaksinesammensetning
DK1228217T3 (da) Konserverede neisseria-antigener
CY2012030I2 (el) Πολυδυναμο εμβολιο προϊοντος συζευξης μηνιγγοκοκκικου πολυσακχαριδιου-πρωτεϊνης
DE60222056D1 (de) Hebestuhl
NO20033556L (no) Farmasöytiske formuleringer
NO20031483L (no) Vaksine
NO20024172D0 (no) Vaksine
IS7564A (is) Lyfjablanda með breytta losun
NO20033882L (no) Vaksine
DE60238075D1 (de) Adjuvierte antigene meningokokkenzusammensetzungen
ATE290845T1 (de) Selbstschäumendes kosmetisches produkt
DK1539089T3 (da) Reducerede aerosol-genererende formuleringer
IS8325A (is) Bóluefni
AU2003282498A8 (en) Hiv vaccine formulations
DE60328408D1 (de) Impfstoff
ES1050889Y (es) Articulo para masticar
ITVI20020019A1 (it) Sedia elettrostatica